论文部分内容阅读
2006年Bryan等~[1]首次明确提出了三阴性乳腺癌(triple negative breast cancer,TNBC)这一概念,主要是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体(HER-2)均为阴性的乳腺癌。2010年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)指出~[2]:雌激素受体(ER)和孕激素受体(PR)阴性是指免疫组化检测中,肿瘤细胞核免疫染色阳性少于1.0%,HER-2阴性是指免疫组化为
For the first time, Bryan et al. [1] clearly put forward the concept of triple negative breast cancer (TNBC) in 2006 mainly for the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth Factor receptor (HER-2) are negative breast cancer. In 2010, the American Society of Clinical Oncology (ASCO) pointed out that [2] the negative of estrogen receptor (ER) and progesterone receptor (PR) means that in immunohistochemical tests, the nuclei of tumor cells are positive for immunostaining In less than 1.0%, HER-2 negative means immunohistochemistry